CL2020002468A1 - Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018) - Google Patents

Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018)

Info

Publication number
CL2020002468A1
CL2020002468A1 CL2020002468A CL2020002468A CL2020002468A1 CL 2020002468 A1 CL2020002468 A1 CL 2020002468A1 CL 2020002468 A CL2020002468 A CL 2020002468A CL 2020002468 A CL2020002468 A CL 2020002468A CL 2020002468 A1 CL2020002468 A1 CL 2020002468A1
Authority
CL
Chile
Prior art keywords
antibodies
progranulin
sortilin
bind
inhibit
Prior art date
Application number
CL2020002468A
Other languages
English (en)
Inventor
Den Brink Edward Van
Ibrahim John Malik
Rønn Lars Christian Biilmann
Jeffrey B Stavenhagen
Søren Christensen
Jan Egebjerg
Arnout Gerritsen
Paul Parren
Jong Rob De
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2020002468A1 publication Critical patent/CL2020002468A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales anti-sortilina que se ha encontrado que son útiles en la corrección de un nivel deficiente de progranulina (PGRN). En particular, pueden usarse estos anticuerpos en el tratamiento de demencia frontotemporal (DFT) y esclerosis lateral amiotrófica (ELA).
CL2020002468A 2015-07-13 2020-09-24 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018) CL2020002468A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
CL2020002468A1 true CL2020002468A1 (es) 2021-01-29

Family

ID=54013862

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018000092A CL2018000092A1 (es) 2015-07-13 2018-01-11 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.
CL2020002468A CL2020002468A1 (es) 2015-07-13 2020-09-24 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018000092A CL2018000092A1 (es) 2015-07-13 2018-01-11 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.

Country Status (35)

Country Link
US (6) US10479835B2 (es)
EP (1) EP3322726B1 (es)
JP (2) JP6979397B2 (es)
KR (1) KR102778576B1 (es)
CN (3) CN107849135A (es)
AR (1) AR105335A1 (es)
AU (1) AU2016292980B2 (es)
BR (1) BR112018000771A2 (es)
CA (1) CA2989739A1 (es)
CL (2) CL2018000092A1 (es)
CO (1) CO2017012988A2 (es)
CR (1) CR20180002A (es)
DO (1) DOP2018000014A (es)
EA (1) EA201890038A1 (es)
EC (1) ECSP18002725A (es)
ES (1) ES3024469T3 (es)
GB (1) GB201512215D0 (es)
HR (1) HRP20250602T1 (es)
HU (1) HUE071424T2 (es)
IL (1) IL256503B (es)
JO (1) JO3710B1 (es)
MA (1) MA42440B1 (es)
MX (1) MX2018000506A (es)
NI (1) NI201800007A (es)
PE (1) PE20181014A1 (es)
PH (1) PH12018500100A1 (es)
PL (1) PL3322726T3 (es)
RS (1) RS66856B1 (es)
RU (1) RU2735639C2 (es)
SV (1) SV2018005613A (es)
TN (1) TN2017000534A1 (es)
TW (1) TWI760305B (es)
UA (1) UA125136C2 (es)
WO (1) WO2017009327A1 (es)
ZA (1) ZA201708613B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
SMT202300110T1 (it) * 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
MX2021012335A (es) * 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
BR112022012230A2 (pt) * 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
AU2021297540A1 (en) * 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
US20250345446A1 (en) 2022-06-23 2025-11-13 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
DK1891966T3 (da) 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
PL3225251T3 (pl) 2006-12-21 2020-06-29 H. Lundbeck A/S Modulacja aktywności proneurotrofin
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
WO2009132656A2 (en) 2008-04-27 2009-11-05 H. Lundbeck A/S Design of specific ligands to sortilin
JP2011524741A (ja) 2008-05-27 2011-09-08 協和発酵キリン株式会社 インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3165537A1 (en) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
EP3991748A3 (en) * 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso

Also Published As

Publication number Publication date
US11548950B2 (en) 2023-01-10
AU2016292980B2 (en) 2022-10-06
ZA201708613B (en) 2021-03-31
MA42440B1 (fr) 2025-05-30
RU2735639C2 (ru) 2020-11-05
CL2018000092A1 (es) 2018-07-06
EA201890038A1 (ru) 2018-06-29
IL256503B (en) 2022-02-01
TWI760305B (zh) 2022-04-11
MX2018000506A (es) 2018-05-11
JO3710B1 (ar) 2021-01-31
RS66856B1 (sr) 2025-06-30
KR20180030045A (ko) 2018-03-21
JP2018529635A (ja) 2018-10-11
RU2018100824A3 (es) 2020-01-17
US10428147B2 (en) 2019-10-01
DOP2018000014A (es) 2018-04-15
EP3322726C0 (en) 2025-03-12
SV2018005613A (es) 2018-02-23
CO2017012988A2 (es) 2018-05-21
US20200190188A1 (en) 2020-06-18
US20210269524A1 (en) 2021-09-02
GB201512215D0 (en) 2015-08-19
HRP20250602T1 (hr) 2025-07-18
KR102778576B1 (ko) 2025-03-07
UA125136C2 (uk) 2022-01-19
US20250277040A1 (en) 2025-09-04
AU2016292980A1 (en) 2018-01-18
CN114478774A (zh) 2022-05-13
US20230159643A1 (en) 2023-05-25
IL256503A (en) 2018-02-28
TW201702273A (zh) 2017-01-16
PH12018500100A1 (en) 2018-07-30
US10889650B2 (en) 2021-01-12
PL3322726T3 (pl) 2025-06-23
HUE071424T2 (hu) 2025-08-28
CN114478775A (zh) 2022-05-13
EP3322726B1 (en) 2025-03-12
WO2017009327A1 (en) 2017-01-19
RU2018100824A (ru) 2019-08-13
ES3024469T3 (en) 2025-06-04
US20180305455A1 (en) 2018-10-25
US10479835B2 (en) 2019-11-19
JP6979397B2 (ja) 2021-12-15
CR20180002A (es) 2018-04-09
AR105335A1 (es) 2017-09-27
JP2022003058A (ja) 2022-01-11
US12331123B2 (en) 2025-06-17
HK1254356A1 (en) 2019-07-19
BR112018000771A2 (pt) 2018-09-25
US20170267761A1 (en) 2017-09-21
PE20181014A1 (es) 2018-06-26
EP3322726A1 (en) 2018-05-23
TN2017000534A1 (en) 2019-04-12
CN107849135A (zh) 2018-03-27
ECSP18002725A (es) 2018-03-31
CA2989739A1 (en) 2017-01-19
NI201800007A (es) 2018-10-18
MA42440A (fr) 2018-05-23

Similar Documents

Publication Publication Date Title
DOP2018000014A (es) Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina
JOP20220242B1 (ar) أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
EA202091540A1 (ru) Антитела к lilrb2
JOP20200132A1 (ar) صيغة مجففة بالتبريد من جسم مضاد أحادي النسيلة ضد ترانس ثيرتين
MX389911B (es) Anticuerpos anti-transtiretina
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX394170B (es) Anticuerpos anti-transtiretina
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
MX395317B (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
SA517381991B1 (ar) أجسام مضادة لترانس ثيرتين
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
ECSP20002935A (es) Agentes, usos y métodos para el tratamiento
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA202090330A1 (ru) Композиции и способы лечения расстройств, связанных со стрессом
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
EA201991471A1 (ru) Способы введения гепсидина
MY193688A (en) Anti-transthyretin antibodies